Key terms
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CYCC news
Mar 19
4:14pm ET
Cyclacel Pharmaceuticals reports Q4 EPS (6.23), consensus ($5.89)
Mar 06
9:17am ET
Cyclacel Pharmaceuticals receives $2.9M R&D tax credit
Jan 30
9:20am ET
Cyclacel terminates CMO Kirschbaum, appoints Schwartz as interim CMO
Jan 19
4:59pm ET
Cyclacel Pharmaceuticals files to sell 411,969 shares of common stock for holder
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 10
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Jan 08
9:24am ET
Cyclacel Pharmaceuticals regains compliance with Nasdaq minimum bid price rule
Dec 22
9:19am ET
Cyclacel Pharmaceuticals prices registered direct offering at $3.315 per share
Dec 21
10:52am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for CYCC
CYCC Financials
Key terms
Ad Feedback
CYCC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CYCC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
